← All Quantumzyme CORP filings

Quantumzyme CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

QTZM
Quantumzyme CORP
10-K/A: Quantumzyme Corp. Amends 10-K for IP Disclosure
Quantumzyme Corp. files Amendment No. 2 to its 2025 10-K to clarify intellectual property ownership related to its CEO and an enzyme for ibuprofen synthesis.
QTZM
Quantumzyme CORP
10-K/A: Quantumzyme Amends 10-K, Reveals Deeper Losses and Going Concern Doubt
Quantumzyme Corp. filed an amendment to its annual report, disclosing increased net losses, a significant working capital deficit, and substantial doubt about its ability to continue as a going concern.
QTZM
Quantumzyme CORP
10-K: Quantumzyme Reports FY2025 Losses, Eyes Enzyme Commercialization
Quantumzyme Corp., an early-stage biotransformation company, reported a net loss of $199,269 for fiscal year 2025 with no revenue, raising substantial doubt about its ability to continue as a going concern.